haemophilus influenzae type a (hia) glycoconjugate vaccine
Vaccineexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 29, 2024 (NCT06465420)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Haemophilus influenzaeImmunity, active
Haemophilus influenzae immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06465420 | Phase 1 | May 29, 2024 | Canadian Center for Vaccinology, InventVacc Biologicals Inc., McGill University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Canadian Center for Vaccinology | Academic/Hospital | 1 | 0 | 1 | 2024 |
| InventVacc Biologicals Inc. | For profit | 1 | 1 | 1 | 2024 |
| McGill University | Academic/Hospital | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1